Previous 10 | Next 10 |
2023-09-02 06:15:00 ET The aim of growth investing is to build significant wealth. Targeting companies that are briskly growing revenue can be a lucrative approach to investing. In the past five years, the genetic diagnostics company Veracyte (NASDAQ: VCYT) has produced cumulati...
Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time. ...
New data are from a retrospective analysis of the Phase 2 STREAM trial Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intellig...
2023-08-17 09:00:00 ET Summary Veracyte posted Q2 FY'23 earnings with continued growth in revenues and cash collections. The company's Decipher acquisition has shown positive results, with an increase in testing volumes. Despite potential investment value, uncertainties remain...
Awards mark Veracyte’s 10 th consecutive honor in the Bay Area and inaugural recognition in San Diego Veracyte, Inc . (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces. Veracyte’s South San Francisco location h...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
2023-08-08 22:05:21 ET Veracyte, Inc. (VCYT) Q2 2023 Earnings Conference Call August 08, 2023, 16:30 ET Company Participants Shayla Gorman - Director, IR Marc Stapley - CEO & Director Rebecca Chambers - EVP & CFO Conference Call Participants M...
2023-08-08 16:43:06 ET Veracyte press release ( NASDAQ: VCYT ): Q2 GAAP EPS of -$0.12 beats by $0.04 . Revenue of $90.32M (+24.0% Y/Y) beats by $7.23M . The company is raising full-year 2023 total revenue guidance to $342 million to $350 million vs $335.77M con...
Grew Total Revenue to $90.3 million, an Increase of 24% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023. “We delivered outstanding second quarter results, ...
2023-08-07 17:35:56 ET Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.14 (-7.7% Y/Y) and the consensus Revenue Estimate is $83.09M (+14.0% Y/Y). Over the last 1 year, ...
News, Short Squeeze, Breakout and More Instantly...
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update...
Findings presented at the ENDO 2024 conference Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive d...
Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from three studies will demonstrate the power of the Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help...